A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization

  • Cancer
  • Hepatocellular Carcinoma (HCC)
  • Unresectable Hepatocellular Carcinoma
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Not yet recruiting

This trial runs in
Country
  • China
Trial Identifier:

NCT06503250 ML45337

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This is a multicenter, retrospective, observational cohort study to describe the effectiveness and safety of Atezo+Bev plus Transarterial Chemoembolization (TACE) among adult patients with unresectable hepatocellular carcinoma (HCC) in real-world clinical practice in China. Eligible patients diagnosed with unresectable HCC initiating the Atezo+Bev and TACE between 28 October 2020 and 31 December 2023 will be included in this study.

      Hoffmann-La Roche Sponsor
      N/A Phase
      NCT06503250, ML45337 Trial Identifier
      Atezolizumab, Bevacizumab, Transarterial Chemoembolization Treatments
      Unresectable Hepatocellular Carcinoma Condition
      Official Title

      Effectiveness and Safety of Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization as Conversion Therapy Among Patients With Initially Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice in China

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Initiating both Atezo+Bev and TACE between 28 October 2020 and 31 December 2023 regardless of sequencing, number of doses/cycles, and type of TACE
      • At least one dose of Atezo+Bev and one cycle of TACE spaced no longer than 4 weeks
      • Diagnosed with HCC and considered as unresectable by any of the below criteria:
      • Predicted insufficient future liver remnant volume (FLRV) after liver resection, OR * Predicted unattainable safe negative tumor margin resection, i.e., R0 resection, OR * "Unresectable" directly documented in the medical records
      Exclusion Criteria
      • No visit record after initiating both Atezo+Bev and TACE
      • Treated with other systemic therapy or resection against HCC
      • Diagnosed with concomitant cancer except for basal cell carcinoma
      • Advanced portal vein tumor thrombosis (PVTT) as defined by: Grade Vp 4, Cheng's Classification Type III or IV, or presence of a tumor thrombus in the main trunk of the portal vein, a portal vein branch contralateral to the primarily involved lobe, or superior mesenteric vein
      • China Liver Cancer (CNLC) Stage IIIb, or history of extrahepatic metastasis
      • Terminal-stage HCC

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Trials

      Use our search to find other trials on ForPatients in related disease areas.

      Unresectable Hepatocellular Carcinoma

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now